• Online Features  This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (27)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Aging/ Geriatrics  • HIV/AIDS  • Prognosis/ Outcomes  • Drug Therapy  • Drug Therapy, Other  • Hematology/ Hematologic Malignancies  • Leukemias/ Lymphomas  • Infectious Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

Dianne Pulte, MD; Adam Gondos, PhD; Hermann Brenner, MD, MPH

Arch Intern Med. 2008;168(5):469-476.

Background  Non-Hodgkin lymphoma (NHL) is the most common hematologic malignant neoplasm in adults. We use the novel technique of period analysis to disclose the most recent trends in survival among adults diagnosed as having NHL on the population level with minimum delay.

Methods  We estimated trends in 5- and 10-year relative survival in patients 15 years or older diagnosed as having NHL in the United States between 1990 and 2004 using data from the Surveillance, Epidemiology, and End Results (SEER) program. We also estimated survival by age, location and histologic type of the tumor, sex, and race to further elucidate trends in survival in this disease.

Results  Overall, 5-year relative survival increased from 50.4% to 66.8%, and 10-year relative survival increased from 39.4% to 56.3% between 1990-1992 and 2002-2004. Improvements were most pronounced in patients younger than 45 years (+26.8 and +27.1 percentage points for 5- and 10-year survival, respectively), but improvements were seen in all age groups, in both sexes, in both nodal and extranodal disease, and in both low-grade and high-grade disease. Improvements in prognosis were less in black patients than in white patients, especially in younger black patients.

Conclusions  Our period analysis discloses a strongly improved outlook for patients diagnosed as having NHL in recent years. Changes in treatment of the disease and a decrease in the number of human immunodeficiency virus–related NHL cases attributable to highly active antiretroviral therapy are probably primarily responsible for these improvements.

Author Affiliations: Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany (Drs Pulte, Gondos, and Brenner); and Weill Cornell Medical Center, New York, New York (Dr Pulte).

CiteULike    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Diverging trends in incidence and mortality, and improved survival of non-Hodgkin's lymphoma, in the Netherlands, 1989-2007
van de Schans et al.
Ann Oncol 2012;23:171-182.
ABSTRACT | FULL TEXT  

Rituximab Maintenance for the Treatment of Patients With Follicular Lymphoma: An Updated Systematic Review and Meta-analysis of Randomized Trials
Vidal et al.
JNCI J Natl Cancer Inst 2011;103:1799-1806.
ABSTRACT | FULL TEXT  

SAR3419: An Anti-CD19-Maytansinoid Immunoconjugate for the Treatment of B-Cell Malignancies
Blanc et al.
Clin. Cancer Res. 2011;17:6448-6458.
ABSTRACT | FULL TEXT  

Is There a Role for Bortezomib Combinations in the Management of Patients With Follicular Lymphoma?
Salles
JCO 2011;29:3349-3350.
FULL TEXT  

Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study
Le Gouill et al.
haematol 2011;96:1128-1135.
ABSTRACT | FULL TEXT  

Upfront immunization with autologous recombinant idiotype Fab fragment without prior cytoreduction in indolent B-cell lymphoma
Navarrete et al.
Blood 2011;117:1483-1491.
ABSTRACT | FULL TEXT  

Improving Relative Survival, But Large Remaining Differences in Survival for Non-Hodgkin's Lymphoma Across Europe and the United States From 1990 to 2004
van de Schans et al.
JCO 2011;29:192-199.
ABSTRACT | FULL TEXT  

Are patients with Hodgkin lymphoma and high-grade non-Hodgkin lymphoma in clinical therapy optimization protocols representative of these groups of patients in Germany?
Terschuren et al.
Ann Oncol 2010;21:2045-2051.
ABSTRACT | FULL TEXT  

Long-Term Follow-Up of Patients With Newly Diagnosed Follicular Lymphoma in the Prerituximab Era: Effect of Response Quality on Survival--A Study From the Groupe d'Etude des Lymphomes de l'Adulte
Bachy et al.
JCO 2010;28:822-829.
ABSTRACT | FULL TEXT  

Improvements in Survival After Follicular Lymphoma by Race/Ethnicity and Socioeconomic Status: A Population-Based Study
Keegan et al.
JCO 2009;27:3044-3051.
ABSTRACT | FULL TEXT  

Superior Antitumor Activity of SAR3419 to Rituximab in Xenograft Models for Non-Hodgkin's Lymphoma
Al-Katib et al.
Clin. Cancer Res. 2009;15:4038-4045.
ABSTRACT | FULL TEXT